Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kell

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|August 24, 2022
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paperMike Dennis, Mhairi Copland, Harpreet Kaur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett, Robert K Hills, Donald Milligan, et al.
Ejhaem|July 18, 2022
Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational studyFarrukh Shah, Paul Telfer, Mark Velangi, et al.
Blood|September 10, 2005
Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cellsRichard G Goodwin, W Jonathan Kell, Peter Laidler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemiaAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Therapeutic Advances in Hematology|October 26, 2020
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative studyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Frontiers in Pharmacology|March 27, 2020
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content ValidityPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Blood|April 3, 2015
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patientsAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four CoursesAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|August 24, 2022
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paperMike Dennis, Mhairi Copland, Harpreet Kaur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trialAlan K Burnett, Robert K Hills, Donald Milligan, et al.
Ejhaem|July 18, 2022
Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational studyFarrukh Shah, Paul Telfer, Mark Velangi, et al.
Blood|September 10, 2005
Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cellsRichard G Goodwin, W Jonathan Kell, Peter Laidler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemiaAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Therapeutic Advances in Hematology|October 26, 2020
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative studyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Frontiers in Pharmacology|March 27, 2020
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content ValidityPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Blood|April 3, 2015
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patientsAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four CoursesAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
Pageof 3